SCHEMBL20133372

SCHEMBL20133372

Cc1ccc(O[C@H]2C[C@H](Oc3ccc(-c4ccc5c6cnccc6n(C)c5c4)cn3)C2)nn1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.35
ATR Q13535 2/20 0.35
TDO2 P48775 1/20 0.34
RET P07949 4/20 0.33
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
RAB9A P51151 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
MAPT P10636 1/20 0.33
MCHR1 Q99705 5/20 0.32
KCNH2 Q12809 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
FAAH O00519 3/20 0.31
MKNK1 Q9BUB5 1/20 0.31
MKNK2 Q9HBH9 1/20 0.31
PIK3CA P42336 1/20 0.31
MTOR P42345 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20120706 0.90 TDO2 (0.35) ATMATRTDO2NPC1POLB
SCHEMBL29547391 0.90 TDO2 (0.35) ATMATRTDO2NPC1POLB
SCHEMBL20120707 0.90 TDO2 (0.35) ATMATRTDO2NPC1POLB
SCHEMBL20120436 0.86 TDO2 (0.37) ATMATRTDO2NPC1POLB
SCHEMBL29547266 0.86 TDO2 (0.37) ATMATRTDO2NPC1POLB
SCHEMBL20120435 0.86 TDO2 (0.37) ATMATRTDO2NPC1POLB
SCHEMBL20120825 0.86 TDO2 (0.38) ATMATRTDO2NPC1POLB
SCHEMBL20129152 0.86 TDO2 (0.38) ATMATRTDO2NPC1POLB
SCHEMBL20120826 0.86 TDO2 (0.38) ATMATRTDO2NPC1POLB
SCHEMBL29547432 0.86 TDO2 (0.38) ATMATRTDO2NPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN ATM 711/4885ATR 1368/4885TDO2 3503/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 ATM 959/4885ATR 1538/4885TDO2 3395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.